Published in AAPS J on August 18, 2006
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev (2012) 1.67
Inhibition of transferrin iron release increases in vitro drug carrier efficacy. J Control Release (2006) 1.54
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther (2010) 1.10
Chaperone-targeting cytotoxin and endoplasmic reticulum stress-inducing drug synergize to kill cancer cells. Neoplasia (2009) 1.06
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. J Hematol Oncol (2014) 0.97
Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med (2011) 0.97
A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer (2011) 0.97
Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells. Leuk Res (2009) 0.96
Thrombotic microangiopathy with targeted cancer agents. Clin Cancer Res (2011) 0.96
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release (2008) 0.95
Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One (2012) 0.94
pH-triggered conformational switching along the membrane insertion pathway of the diphtheria toxin T-domain. Toxins (Basel) (2013) 0.93
Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin. MAbs (2013) 0.93
Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer (2013) 0.92
Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum. Adv Drug Deliv Rev (2007) 0.92
Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases. Toxins (Basel) (2012) 0.91
Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells. J Immunol Methods (2010) 0.89
Abrin immunotoxin: targeted cytotoxicity and intracellular trafficking pathway. PLoS One (2013) 0.88
Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy. Curr Pharm Des (2014) 0.88
Use of ribosome-inactivating proteins from Sambucus for the construction of immunotoxins and conjugates for cancer therapy. Toxins (Basel) (2011) 0.86
Listeriolysin O as cytotoxic component of an immunotoxin. Protein Sci (2009) 0.86
Sensitivity of cancer cells to truncated diphtheria toxin. PLoS One (2010) 0.86
GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. Oncotarget (2014) 0.85
Design of targeted B cell killing agents. PLoS One (2011) 0.85
Retrograde traffic in the biosynthetic-secretory route. Histochem Cell Biol (2008) 0.85
Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem (2010) 0.85
Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy (2009) 0.84
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer (2011) 0.84
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci (2012) 0.83
Assessment of selective toxicity of insect cell expressed recombinant A1-GMCSF protein toward GMCSF receptor bearing tumor cells. Res Pharm Sci (2012) 0.83
Structural and functional characterization of the interaction of the photosensitizing probe methylene blue with Torpedo californica acetylcholinesterase. Protein Sci (2012) 0.81
Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells. PLoS One (2007) 0.81
BiP negatively affects ricin transport. Toxins (Basel) (2013) 0.80
Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol (2015) 0.80
Ribosome-inactivating and related proteins. Toxins (Basel) (2015) 0.80
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin Oncol (2015) 0.79
Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells. Oncotarget (2016) 0.79
Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered (2013) 0.79
The core-inversible micelles for hydrophilic drug delivery. Chem Commun (Camb) (2013) 0.79
Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. Transl Oncol (2008) 0.79
In vivo characterization of fusion protein comprising of A1 subunit of Shiga toxin and human GM-CSF: Assessment of its immunogenicity and toxicity. Iran Biomed J (2010) 0.79
Fully human MAP-fusion protein selectively targets and eliminates proliferating CD64(+) M1 macrophages. Immunol Cell Biol (2016) 0.79
Pseudomonas aeruginosa exotoxin A reduces chemoresistance of oral squamous carcinoma cell via inhibition of heat shock proteins 70 (HSP70). Yonsei Med J (2010) 0.78
Membrane translocation assay based on proteolytic cleavage: application to diphtheria toxin T domain. Biochim Biophys Acta (2014) 0.78
A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas. Drug Des Devel Ther (2015) 0.78
Countering immunotoxin immunogenicity. Br J Cancer (2016) 0.78
An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis (2013) 0.78
In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. J Cancer Res Clin Oncol (2014) 0.78
Immunotoxins: a promising treatment modality for metastatic melanoma? Ochsner J (2010) 0.77
Immunotoxins: a review of their use in cancer treatment. J Stem Cells Regen Med (2006) 0.77
Structural complementation of the catalytic domain of pseudomonas exotoxin A. J Mol Biol (2013) 0.77
Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep (2016) 0.77
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int J Mol Sci (2017) 0.75
Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. Acta Naturae (2017) 0.75
Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutants. Cancer Sci (2015) 0.75
A novel recombinant immunotoxin with the smallest ribosome-inactivating protein Luffin P1: T-cell cytotoxicity and prolongation of allograft survival. J Cell Mol Med (2009) 0.75
Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. PLoS One (2008) 0.75
Diphtheria Toxin/Human B-Cell Activating Factor Fusion Protein Kills Human Acute Lymphoblastic Leukemia BALL-1 Cells: An Experimental Study. Chin J Cancer Res (2012) 0.75
Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels. Int J Med Sci (2015) 0.75
Abrin P2 suppresses proliferation and induces apoptosis of colon cancer cells via mitochondrial membrane depolarization and caspase activation. Acta Biochim Biophys Sin (Shanghai) (2016) 0.75
HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis. Oncotarget (2017) 0.75
Fungal Ribotoxins: A Review of Potential Biotechnological Applications. Toxins (Basel) (2017) 0.75
Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation. Biomedicines (2017) 0.75
Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther (2017) 0.75
Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16]. J Cancer Res Clin Oncol (2017) 0.75
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A (1988) 6.14
The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem (1987) 5.79
Single-chain antigen-binding proteins. Science (1988) 5.29
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 4.65
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell (1978) 4.06
The crystal structure of diphtheria toxin. Nature (1992) 3.80
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci U S A (1986) 3.41
The IL-2/IL-2 receptor system: a current overview. Cell (1993) 3.33
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood (2003) 3.25
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene (2000) 3.12
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med (1997) 2.76
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 2.24
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature (1989) 2.13
Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci U S A (1986) 2.12
Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci U S A (1990) 2.12
Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol (2003) 1.99
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol (2000) 1.95
B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci U S A (1991) 1.89
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A (1998) 1.88
Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci U S A (1980) 1.85
Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science (1972) 1.82
Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry (1996) 1.81
A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem (1992) 1.78
Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem (1987) 1.75
Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem (1988) 1.73
Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res (1980) 1.69
Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol. J Biol Chem (1999) 1.69
Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res (2004) 1.65
Refined structure of monomeric diphtheria toxin at 2.3 A resolution. Protein Sci (1994) 1.64
Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci U S A (1995) 1.63
Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem (1991) 1.61
A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res (2003) 1.57
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J (2000) 1.55
Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem (1989) 1.54
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem (1995) 1.52
Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl (2003) 1.51
Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk Res (2002) 1.49
Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci U S A (1987) 1.48
Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol (2003) 1.46
Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem (1994) 1.43
Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol (2000) 1.39
Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem (1992) 1.38
Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res (1998) 1.38
The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res (1998) 1.38
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer (1999) 1.34
Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res (1991) 1.34
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res (2000) 1.33
Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol Microbiol (1997) 1.33
Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science (1970) 1.29
Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A (1999) 1.29
Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res (1996) 1.28
Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng (1987) 1.27
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem (1990) 1.26
Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res (2000) 1.26
Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res (1991) 1.26
Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science (1987) 1.25
Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood (1997) 1.24
Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev (2003) 1.24
Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med (1988) 1.23
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A (1996) 1.21
Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A (2000) 1.20
Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med (1996) 1.19
Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J (1995) 1.19
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res (1988) 1.16
Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood (1999) 1.16
The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol (1997) 1.15
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res (2002) 1.15
A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood (1996) 1.15
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res (2002) 1.15
Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1992) 1.14
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res (2004) 1.14
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res (2002) 1.14
Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res (1999) 1.14
Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell (1980) 1.13
A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res (2003) 1.13
Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem (1986) 1.13
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res (2000) 1.13
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma (2002) 1.13
Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc Natl Acad Sci U S A (1996) 1.13
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia (2003) 1.12
Cytotoxic activities of a fusion protein comprised of TGF alpha and Pseudomonas exotoxin. FASEB J (1989) 1.12
Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc Natl Acad Sci U S A (1991) 1.12
Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res (2003) 1.11
Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood (1999) 1.10
Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant (2004) 1.09
A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res (2002) 1.09
The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia (2001) 1.09
Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J Biol Chem (1990) 1.08